News from ODYSSEY OUTCOMES: Effects of PCSK9 inhibition on total cardiovascular disease burden New US Cholesterol Guidelines: The good, the bad and the ugly Statins versus PCSK9 inhibitors: new metabolomic analysis New meta-analysis of PCSK9 inhibitors: a mortality benefit or not?Coronary artery calcium in familial hypercholesterolaemia Stratifying risk in familial hypercholesterolaemia: does coronary artery calcium have a role?ODYSSEY OUTCOMES Economics Study: How can we get the best value from PCSK9 inhibitors?Alirocumab safe in patients with diabetes mellitus

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & Objectives Mission Statement Editorial Board Partnership & Outreach Forthcoming Meetings

Download NowUNIQUE FREE APPAdvances in lipid lowering - a clinical guide

AHA Scientific Sessions 2018

ODYSSEY OUTCOMES Economic Study

Novel lipoprotein(a) antisense therapy looks good

ODYSSEY OUTCOMES total events analysis

New US Cholesterol Guidelines

News from ESC Congress 2018

News from ISA 2018

Most viewed

SAFEHEART: Consider more than coronary complications in FH Is lowering lipoprotein(a) beneficial when LDL-C is very low? EVOPACS Why the 2017 ESC/EAS practical guidance on PCSK9 inhibition is needed VIDEO: Perspective on the ODYSSEY OUTCOMES Economic Study What’s in the PCSK9 pipeline? How best to optimise PCSK9 inhibition, considering findings from FOURIER and ODYSSEY Outcomes New meta-analysis of PCSK9 inhibitors: a mortality benefit or not? Could PCSK9 inhibitors be used in FH children? BANTING

Most viewed

SAFEHEART: Consider more than coronary complications in FH

PCSK9 Forum Inhibitors and Health Economics

The value of PCSK9 inhibition in very high risk patients is a Hot Topic in the light of recent data from the ODYSSEY OUTCOMES Economics Study. How do these data relate to the current clinical pathway used in the European setting?

PCSK9 Forum Editor Professor Anthony Wierzbicki (Guys and St. Thomas’ Hospital London, UK) puts the results in context.
Watch the video

Perspective on the ODYSSEY OUTCOMES Economic Study
Watch the video

PCSK9 inhibitors: How do we weigh up the benefit versus cost of treatment?
Watch the video

Hot Topics

Coronary artery calcium in familial hypercholesterolaemia

Coronary artery calcium may have a role in stratifying short-term risk in patients with familial hypercholesterolaemia (FH, inherited high cholesterol), according to a new study. This noninvasive approach may have value in targeting treatment with a PCSK9 inhibitor to those patients at highest risk.

Read the report

VIDEO: Is coronary artery calcium a risk assessment too in FH?
Watch the video

VIDEO: Severe FH: how to define?
Watch the video

VIDEO: ESC/EAS Task Force guidance for PCSK9 inhibitors
Watch the video

From the Editors

Did someone say “Beyond LDL-cholesterol”?

PCSK9 Forum Editor Professor John Chapman (Pitié-Salpétrière University Hospital, and Sorbonne University, Paris, France) discusses how ‘OMICS’ technologies could provide a precision medicine approach to managing non-LDL lipids.

Read the report